
WHAT IS CLAIMED IS:

1. A veterinary formulation for treating or preventing a parasitic infestation in an animal comprising:

(a) a 1-aryl-5-alkyl or 5-haloalkylpyrazole of formula (IA) or a veterinarily acceptable salt thereof,



(IA)

wherein:

R_{2a} is $-S(O)_mR_{11a}$;

R_{3a} is methyl, ethyl or C_1-C_4 haloalkyl;

R_{4a} is halogen;

R_{6a} is C_1-C_4 alkyl or haloalkyl;

R_{13a} is halogen;

R_{11a} is C_1-C_4 haloalkyl; and

m is 0, 1 or 2;

(b) a veterinarily acceptable carrier; and


(c) optionally a crystallization inhibitor.

2. A composition for the treatment or prevention of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier, at least one formamidine compound in a second veterinarily acceptable carrier, and optionally at least one crystallization inhibitor, wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are compartmentalized together, and not in fluid

communication with, the formamidine compound(s) and the second veterinarily acceptable carrier.

3. The composition of claim 2, wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are in one cavity of a dual-cavity container and the formamidine compound(s) and the second veterinarily acceptable carrier are in a second cavity of a dual-cavity container, wherein the first cavity is defined by a front wall and a divider wall; and the second cavity is defined by a rear wall and the divider wall.

4. The composition of claim 2, wherein at least one 1-arylpyrazole compound has formula (IB):



(IB)

wherein:

R_{1b} is alkyl, CN or halogen;

R_{2b} is $S(O)_nR_{14b}$ or 4,5-dicyanoimidazol-2-yl or haloalkyl;

R_{14b} is alkyl or haloalkyl;

R_{3b} is a hydrogen, halogen, $-NR_{7b}R_{8b}$, $-S(O)_mR_{9b}$, $-C(O)R_{9b}$, $-C(O)OR_{9b}$, alkyl, haloalkyl, $-OR_{10b}$ or an $-N=C(R_{11b})(R_{12b})$;

R_{6b} is a halogen, haloalkyl, haloalkoxy, $S(O)_qCF_3$ or SF_5 group;

R_{7B} and R_{8B} independently represent a hydrogen, alkyl, haloalkyl, -C(O)alkyl, $-S(O)_rCF_3$, acyl or alkoxycarbonyl; or

R_{7b} and R_{8b} can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;

R_{9b} is an alkyl or haloalkyl;

R_{10b} is hydrogen, alkyl or haloalkyl;

R_{11b} is hydrogen or alkyl radical;

R_{12b} is an optionally substituted aryl or an optionally substituted heteroaryl group;

R_{4b} and R_{13b} represent, independently of one another, hydrogen, halogen CN or NO_2;

m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; and

Z represents a trivalent nitrogen atom or a C-R_{13b} radical, the three other valencies of the carbon atom forming part of the aromatic ring.

5. The composition of claim 4, wherein:

R_{1b} is methyl, CN or halogen;

R_{2b} is $S(O)_nR_{14b}$;

R_{14b} is C_1-C_6-alkyl or C_1-C_6-haloalkyl;

R_{3b} is $-NR_{7b}R_{8b}$,

R_{7b} and R_{8b} independently represent a hydrogen, C_1-C_6-alkyl, C_1-C_6-haloalkyl, -C(O)C_1-C_6-alkyl, $-S(O)_rCF_3$, C_1-C_6-acyl or C_1-C_6-alkoxycarbonyl radical;

R_{6b} is a halogen, C_1-C_6-haloalkyl, or C_1-C_6-haloalkoxy;

m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and

Z is a C-R_{13b} radical.

6. The composition of claim 4, wherein:

R_{1b} is methyl, CN or halogen;

R_{2b} is $S(O)_nR_{14b}$;

R_{14b} is C_1-C_6-alkyl or C_1-C_6-haloalkyl;

R_{3b} is alkyl or haloalkyl;

R_{6b} is a halogen, C_1-C_6-haloalkyl, or C_1-C_6-haloalkoxy;

m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and

Z is a C-R_{13b} radical.

7. The composition of claim 2, wherein the first veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof.


8. The composition of claim 2, wherein the second veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds, aliphatic carboxylic acid esters, aromatic

carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof.

9. The composition of claim 2, wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof.

10. The composition of claim 2, wherein the second veterinarily acceptable carrier comprises an aprotic solvent with a dielectric constant of about 2 to about 30.

11. A composition for the treatment and prevention of a parasitic infestation in an animal comprising at least one formamidine compound; at least one 1-arylpyrazole compound of formula (IA), or veterinarily acceptable salts thereof,



(IA)

wherein:

R_{2a} is $-S(O)_mR_{11a}$;

R_{3a} is methyl, ethyl or C_1-C_4 haloalkyl;

R_{4a} is halogen;

R_{6a} is C_1-C_4 alkyl or haloalkyl;

R_{13a} is halogen;


R_{11a} is C_1-C_4 haloalkyl; and

m is 0, 1 or 2;

at least one veterinarily acceptable carrier; and

optionally at least one crystallization inhibitor.

12. The composition of claim 2 or 11, wherein at least one formamidine compound has the formula (II):



(II)

wherein:

x is an integer from 0-5;


R_{14} is alkyl, halogen or -OC(=O)NR_aR_b,

wherein R_a and R_b are independently hydrogen or alkyl;

R_{15} is hydrogen or alkyl;

R_{16} is hydrogen or alkyl; and

R_{17} is hydrogen, alkyl or



13. The composition of claim 2 or 11, wherein at least one formamidine compound is amitraz, formetanate, chloromebuform, formparanate or chlodimeform.

14. The composition of claim 11, wherein the 1-arylpyrazole compound(s) is combined with a first veterinarily acceptable carrier and the formamidine compound(s) is combined with a second veterinarily acceptable carrier; and wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are compartmentalized together, and not in fluid communication with, the formamidine compound(s) and the second veterinarily acceptable carrier.

15. A composition for the treatment and prevention of a parasitic infestation in an animal comprising at least one formamidine compound and at least one aprotic solvent with a dielectric constant of about 2 to about 30, wherein the composition is stable for at least 24 months at 25° C.

16. The composition of claim 15, wherein at least one formamidine compound is amitraz.

17. The composition of claim 15, wherein the aprotic solvent(s) with a dielectric constant of about 2 to about 30 has a water content of less than about 0.05% (w/w).

18. The composition of claim 15, wherein the aprotic solvent(s) with a dielectric constant of about 2 to about 30 is a C_1-C_{10} carboxylic acid ester, a phenyl carboxylic acid ester, a carboxylic acid benzyl ester, a benzoic acid C_1-C_4 alkyl ester, a C_1-C_6 saturated aliphatic

ketone, or a mixture thereof.

19. The composition of claim 15, comprising at least two aprotic solvents with a dielectric constant of about 2 to about 30, wherein a dissipation of an unpleasant odor from the composition occurs within about 5 minutes to within about 25 minutes after application.

20. A method for the treatment or prevention of a parasitic infestation in an animal comprising administering an effective amount of the composition of claim 2 to the animal.

21. The method of claim 20, wherein at least one 1-arylpyrazole compound is fipronil.

22. The method of claim 20, wherein at least one formamidine compound is amitraz.

23. The method of claim 20, wherein the composition is administered using a dual-cavity container, wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are administered from a first cavity of the dual-cavity container and the formamidine compound(s) and the second veterinarily acceptable carrier are administered from a second cavity of the dual-cavity container.

24. The method of claim 22, wherein the 1-arylpyrazole compound(s) and the formamidine compound(s) are administered simultaneously.

25. A method for the treatment or prevention of a parasitic infestation in an animal comprising administering an effective amount of the composition of claim 11 to the animal.

26. The method of claim 25, wherein the 1-arylpyrazole compound(s) is in a first veterinarily acceptable carrier, and the formamidine compound(s) is in a second veterinarily acceptable carrier; wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are compartmentalized together, and not in fluid communication with, the formamidine compound(s) and the second veterinarily acceptable carrier.

27. The method of claim 26, wherein the 1-arylpyrazole compound(s) and the formamidine compound(s) are administered simultaneously.

28. The method of claim 25, wherein at least one formamidine compound is amitraz.

29. A method for the treatment or prevention of a parasitic infestation in an animal comprising administering to the animal an effective amount of a composition comprising at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier and at least one formamidine compound in a second veterinarily acceptable carrier from a dual-cavity container, wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are in one cavity of the dual-cavity container and the formamidine compound(s) and the second veterinarily acceptable carrier are in a second cavity of the dual-cavity container; and wherein the first cavity is defined by a front wall and a divider wall, and the second cavity is defined by a rear wall and the divider wall.

30. The method of claim 29, wherein at least one 1-arylpyrazole compound is fipronil.

31. The method of claim 29, wherein the at least one 1-arylpyrazole compound is 3-cyano-1-(2-chloro-6-fluoro-4-trifluoromethylphenyl)-4-dichlorofluoromethylsulfinyl-5-methyl-1*H*-pyrazole.


32. The method of claim 29, wherein at least one formamidine compound is amitraz.

33. The method of claim 29, wherein the 1-arylpyrazole compound(s) and the formamidine compound(s) are administered simultaneously.

34. A kit for the treatment or prevention of a parasitic infestation in an animal, comprising: at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier, at least one formamidine compound in a second veterinarily acceptable carrier, and a multiple-cavity container; wherein the 1-arylpyrazole compound(s) in a first veterinarily acceptable carrier is in a first cavity of the multiple-cavity container and the formamidine compound(s) in a second veterinarily acceptable carrier is in a second cavity of the multiple-cavity container; and wherein the first cavity is defined by a front wall and a divider wall, and the second cavity is defined by a rear wall and the divider wall.

CLAIMS

1. A composition for the treatment of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound of formula (IB):



(IB)

wherein:

R_{1b} is alkyl, CN or halogen;

R_{2b} is $S(O)_nR_{14b}$ or 4,5-dicyanoimidazol-2-yl or haloalkyl;

R_{14b} is alkyl or haloalkyl;

R_{3b} is a hydrogen, halogen, $-NR_{7b}R_{8b}$, $-S(O)_mR_{9b}$, $-C(O)R_{9b}$, $-C(O)OR_{9b}$, alkyl, haloalkyl, $-OR_{10b}$ or an $-N=C(R_{11b})(R_{12b})$;

R_{6b} is a halogen, haloalkyl, haloalkoxy, $S(O)_qCF_3$ or SF_5 group;

R_{7B} and R_{8B} independently represent a hydrogen, alkyl, haloalkyl, -C(O)alkyl, $-S(O)_rCF_3$, acyl or alkoxycarbonyl; or

$R_{7b}$and R_{8b} can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;

R_{9b} is an alkyl or haloalkyl;

R_{10b} is hydrogen, alkyl or haloalkyl;

R_{11b} is hydrogen or alkyl radical;

R_{12b} is an optionally substituted aryl or an optionally substituted heteroaryl group;


R_{4b} and R_{13b} represent, independently of one another, hydrogen, halogen CN or NO_2;

m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; and

Z represents a trivalent nitrogen atom or a C-R_{13b} radical, the three other valencies of the carbon atom forming part of the aromatic ring,

in a first veterinarily acceptable carrier;

at least one formamidine compound of formula (II):



(II)

wherein:

x is an integer from 0-5;


R_{14} is alkyl, halogen or -OC(=O)NR_aR_b,

wherein R_a and R_b are independently hydrogen or alkyl;

R_{15} is hydrogen or alkyl;

R_{16} is hydrogen or alkyl; and

R_{17} is hydrogen, alkyl or



,

in a second veterinarily acceptable carrier; and optionally at least one crystallization inhibitor, wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are compartmentalized together, and not in fluid communication with, the formamidine compound(s) and the second veterinarily acceptable carrier.

2. The composition of claim 1, wherein the 1-arylpyrazole compound(s) of Formula (IB) and the first veterinarily acceptable carrier are in one cavity of a dual-cavity container and the formamidine compound(s) of Formula (II) and the second veterinarily acceptable carrier are in a second cavity of a dual-cavity container, wherein the first cavity is defined by a front wall and a divider wall; and the second cavity is defined by a rear wall and the divider wall.

3. The composition of claim 1, wherein in the 1-arylpyrazole of Formula (IB):

R_{1b} is methyl, CN or halogen;

R_{2b} is $S(O)_nR_{14b}$;

R_{14b} is C_1-C_6-alkyl or C_1-C_6-haloalkyl;

R_{3b} is $-NR_{7b}R_{8b}$,

R_{7b} and R_{8b} independently represent a hydrogen, C_1-C_6-alkyl, C_1-C_6-haloalkyl, $-C(O)C_1$-C_6-alkyl, $-S(O)_rCF_3$, C_1-C_6-acyl or C_1-C_6-alkoxycarbonyl radical;

R_{6b} is a halogen, C_1-C_6-haloalkyl, or C_1-C_6-haloalkoxy;

m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and

Z is a C-R_{13b} radical.

4. The composition of claim 1, wherein in the 1-arylpyrazole of Formula (IB):

R_{1b} is methyl, CN or halogen;

R_{2b} is $S(O)_nR_{14b}$;

R_{14b} is C_1-C_6-alkyl or C_1-C_6-haloalkyl;

R_{3b} is alkyl or haloalkyl;

R_{6b} is a halogen, C_1-C_6-haloalkyl, or C_1-C_6-haloalkoxy;

m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and

Z is a C-R_{13b} radical.

5. The composition of claim 1, wherein the first veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof.

6. The composition of claim 1, wherein the second veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds, aliphatic carboxylic acid esters, aromatic carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof.

7. The composition of claim 1, wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof.

8. The composition of claim 1, wherein the second veterinarily acceptable carrier comprises an aprotic solvent with a dielectric constant of about 2 to about 30.

9. The composition of claim 1, wherein at least one formamidine compound is amitraz, formetanate, chloromebuform, formparanate or chlodimeform.

10. The composition of claim 1, wherein the first veterinarily acceptable carrier comprises an organic solvent with a dielectric constant of about 10 to about 35.

11. The composition of claim 10, wherein the first veterinarily acceptable carrier comprises C_1-C_{10} alcohols or esters thereof, C_{10}-C_{18} saturated fatty acids or

esters thereof, C_{10}-C_{18} monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, glycerol monoesters, glycerol diesters, glycerol triesters, glycols, glycol ethers, glycol esters, glycol carbonates, polyethylene glycols or monoethers, diethers, monoesters or diesters thereof.

12. The composition of claim 11, wherein the first veterinarily acceptable carrier comprises a C_1-C_{10} alcohol, a glycol ether, a polyethylene glycol monoether or a polyethylene glycol diether, or a mixture thereof.

13. The composition of claim 1, wherein the 1-arylpyrazole of Formula (IB) is fipronil.

14. The composition of claim 1, wherein the 1-arylpyrazole of Formula (IB) is amitraz.

15. The composition of claim 13, wherein fipronil is present at a concentration of about 5% (w/v) to about 15% (w/v).

16. The composition of claim 14, wherein amitraz is present at a concentration of about 1% (w/v) to about 30% (w/v).

17. The composition of claim 1, wherein the composition comprises fipronil at a concentration of about 5% (w/v) to about 15% (w/v) and amitraz at a concentration of about 5% (w/v) to about 20% (w/v).

18. The composition of claim 1, wherein the composition further comprises an additional parasiticidal active agent.

19. The composition of claim 18, wherein the additional parasiticidal active agent is an avermectin or milbemycin compound, an insect growth regulator, a pyrethroid, a benzimidazole, an imidazothiazole, praziquantel, an isoxazoline compound, an amino acetonitrile compound or an aryloazol-2-yl cyanoethylamino compound.

20. The composition of claim 19, wherein the insect growth regulator is methoprene or pyriproxyfen.

21. The composition of claim 19, wherein the avermectin or milbemycin compound is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, moxidectin, nemadectin or milbemycin oxime.

22. The composition of claim 1, wherein the composition comprises fipronil at a concentration of about 5% (w/v) to about 15% (w/v) and amitraz at a concentration of about 5% to about 20% (w/v); wherein the first veterinarily acceptable carrier comprises ethanol, isopropanol, diethyleneglycol monoethyl ether, N-methylpyrrolidone, or a mixture thereof; and wherein the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, ethyl benzoate, benzyl benzoate or octyl acetate, or a mixture thereof.